Skip to main content

Table 3 Most common adverse events by treatment group, age, and type of neuropathic pain

From: Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies

 

Placebo, n (%)a

Pregabalin 150

mg/day, n (%)a

Pregabalin 300

mg/day, n (%)a

Pregabalin 600

mg/day, n (%)a

Adverse event

DPN

(n = 558)

PHN

(n = 363)

DPN

(n = 176)

PHN

(n = 251)

DPN

(n = 266)

PHN

(n = 230)

DPN

(n = 513)

PHN

(n = 159)

Dizziness

        

   Age 18-64 y

16 (4.4)

9 (13.2)

7 (5.5)

4 (7.0)

40 (22.0)

11 (24.0)

85 (24.7)

23 (48.9)

   Age 65-74 y

8 (5.1)

10 (7.0)

3 (7.7)

13 (14.1)

16 (25.8)

25 (39.1)

46 (33.1)

25 (36.2)

   Age ≥75 y

2 (5.9)

17 (11.2)

2 (20.0)

22 (21.6)

6 (27.3)

37 (30.6)

11 (36.7)

13 (30.2)

Somnolence

        

   Age 18-64 y

14 (3.8)

5 (7.4)

5 (3.9)

7 (12.3)

24 (13.2)

3 (6.7)

45 (13.1)

13 (27.7)

   Age 65-74 y

2 (1.3)

5 (3.5)

2 (5.1)

9 (9.8)

11 (17.7)

14 (21.9)

16 (11.5)

20 (29.0)

   Age ≥75 y

0

10 (6.6)

2 (20.0)

12 (11.8)

3 (13.6)

25 (20.7)

7 (23.3)

11 (25.6)

Peripheral edema

        

   Age 18-64 y

27 (7.4)

2 (2.9)

6 (4.7)

3 (5.3)

15 (8.2)

3 (6.7)

53 (15.4)

6 (12.8)

   Age 65-74 y

10 (6.3)

6 (4.2)

3 (7.7)

9 (9.8)

9 (14.5)

8 (12.5)

24 (17.3)

12 (17.4)

   Age ≥75 y

3 (8.8)

6 (3.9)

1 (10.0)

7 (6.9)

2 (9.1)

24 (19.8)

5 (16.7)

4 (9.3)

Asthenia

        

   Age 18-64 y

11 (3.0)

4 (5.9)

3 (2.4)

2 (3.5)

8 (4.4)

3 (6.7)

24 (7.0)

3 (6.4)

   Age 65-74 y

0

6 (4.2)

0

6 (6.5)

4 (6.5)

0

14 (10.1)

7 (10.1)

   Age ≥75 y

1 (2.9)

7 (4.6)

1 (10.0)

5 (4.9)

1 (4.5)

4 (3.3)

6 (20.0)

2 (4.7)

Dry mouth

        

   Age 18-64 y

6 (1.6)

2 (2.9)

1 (0.8)

5 (8.8)

6 (3.3)

0

18 (5.2)

8 (17.0)

   Age 65-74 y

1 (0.6)

6 (4.2)

0

9 (9.8)

4 (6.5)

6 (9.4)

10 (7.2)

9 (13.0)

   Age ≥75 y

0

5 (3.3)

2 (20.0)

5 (4.9)

3 (13.6)

8 (6.6)

2 (6.7)

6 (14.0)

Weight gain

        

   Age 18-64 y

3 (0.8)

1 (1.5)

6 (4.7)

3 (5.3)

9 (4.9)

4 (8.9)

34 (9.9)

5 (10.6)

   Age 65-74 y

1 (0.6)

2 (1.4)

1 (2.6)

1 (1.1)

1 (1.6)

2 (3.1)

10 (7.2)

9 (13.0)

   Age ≥75 y

1 (2.9)

0

1 (10.0)

1 (1.0)

0

8 (6.6)

1 (3.3)

5 (11.6)

Infection

        

   Age 18-64 y

25 (6.8)

2 (2.9)

10 (7.9)

9 (15.8)

17 (9.3)

4 (8.9)

10 (2.9)

1 (2.1)

   Age 65−74 y

8 (5.1)

7 (4.9)

4 (10.3)

7 (7.6)

5 (8.1)

3 (4.7)

6 (4.3)

1 (1.4)

   Age ≥75 y

2 (5.9)

3 (2.0)

0

6 (5.9)

1 (4.5)

11 (9.1)

1 (3.3)

2 (4.7)

  1. aSee Table 1 for total number of patients in each age group by treatment group and neuropathic pain condition
  2. DPN: diabetic peripheral neuropathy; PHN: postherpetic neuralgia
Back to article page

BMC Primary Care

ISSN: 2731-4553

Contact us